ASX:MSB
ASX:MSBBiotechs

Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?

Mesoblast Limited recently released updated revenue guidance, projecting gross revenue of over US$30.0 million from Ryoncil® sales for the quarter ending December 31, 2025, and announced a collaborative pivotal trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network for Ryoncil® in adults with severe acute graft versus host disease. This combination of higher sales forecasts and expanded clinical research signals an important step as Mesoblast seeks to broaden both its...
ASX:AX1
ASX:AX1Specialty Retail

Does Accent Group’s (ASX:AX1) Transparent MySale Losses Reveal a New Approach to Cost Discipline?

Earlier this month, Accent Group Limited released updated earnings guidance for the 2026 financial year, forecasting first half EBIT in the A$55 million to A$60 million range and full-year EBIT between A$85 million and A$95 million, accounting for nonrecurring losses from closing its MySale operations. A unique aspect of this update is the explicit inclusion of nonrecurring losses tied to the MySale closure, providing a more transparent view of the company’s operational expectations and cost...
ASX:WOR
ASX:WORConstruction

Worley (ASX:WOR) Valuation Revisited Following Upbeat 2026 Earnings Growth Guidance

Worley (ASX:WOR) has caught investor attention after issuing new earnings guidance for the 2026 financial year, projecting higher revenue growth compared to its performance in FY2025. This update could reshape market expectations moving forward. See our latest analysis for Worley. The updated 2026 guidance follows a choppy year for Worley’s share price. The price has shifted lower in recent months but showed some resilience after the new outlook was announced. While the 1-year total...